Literature DB >> 11380714

No more tears: a randomized controlled double-blind trial of Amethocaine gel vs. placebo in the management of procedural pain in neonates.

J Moore1.   

Abstract

AIM: During a comparative double-blind study, the efficacy of Amethocaine local anaesthetic gel was compared with that of a placebo gel to establish their effect on the reduction of behavioural and physiological responses to pain in neonates.
METHOD: Forty infants were included in the trial, 20 being randomly assigned to each group. After topical application of either Amethocaine or the placebo for 30 minutes, cannulation was performed using a 24 gauge cannula. Assessment of pain was made with the aid of four point assessment tool incorporating facial expression, cry and heart rate changes and ease of cannulation. Additional baseline data were obtained including sex, gestation, weight and previous experience of cannulation, and analysed using Statistical Package for Social Sciences (SPSS).
RESULTS: Good analgesic effects were demonstrated in the Amethocaine group, as there was a high level of significance (P < 0.01) in the difference in pain scores between the two groups using a Mann-Whitney U-test. There was no correlation between gestation or weight and the degree of pain experienced during painful procedures. No significant relationship was found between cannulation and the degree of pain experienced.
CONCLUSION: It can, therefore, be concluded that Amethocaine gel is an effective local anaesthetic in the management of skin puncturing procedural pain in neonates, and that all infants regardless of maturity, weight or previous experiences probably experience a similar degree of pain and therefore warrant effective and appropriate analgesic intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380714     DOI: 10.1046/j.1365-2648.2001.01776.x

Source DB:  PubMed          Journal:  J Adv Nurs        ISSN: 0309-2402            Impact factor:   3.187


  9 in total

Review 1.  Blood sampling in infants (reducing pain and morbidity).

Authors:  Olga Kapellou
Journal:  BMJ Clin Evid       Date:  2009-01-07

Review 2.  Blood sampling in infants (reducing pain and morbidity).

Authors:  Olga Kapellou
Journal:  BMJ Clin Evid       Date:  2011-04-05

Review 3.  A critical review of the topical local anesthetic amethocaine (Ametop) for pediatric pain.

Authors:  Lisa O'Brien; Anna Taddio; Dorothy A Lyszkiewicz; Gideon Koren
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 4.  Topical anaesthesia for needle-related pain in newborn infants.

Authors:  Jann P Foster; Christine Taylor; Kaye Spence
Journal:  Cochrane Database Syst Rev       Date:  2017-02-04

5.  Nociceptive brain activity as a measure of analgesic efficacy in infants.

Authors:  Caroline Hartley; Eugene P Duff; Gabrielle Green; Gabriela Schmidt Mellado; Alan Worley; Richard Rogers; Rebeccah Slater
Journal:  Sci Transl Med       Date:  2017-05-03       Impact factor: 17.956

6.  How effective is tetracaine 4% gel, before a peripherally inserted central catheter, in reducing procedural pain in infants: a randomized double-blind placebo controlled trial [ISRCTN75884221].

Authors:  Brigitte Lemyre; Rebecca Sherlock; Debora Hogan; Isabelle Gaboury; Colline Blanchard; David Moher
Journal:  BMC Med       Date:  2006-05-03       Impact factor: 8.775

7.  Percutaneous dermal drug delivery for local pain control.

Authors:  Sujatha Tadicherla; Brian Berman
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

Review 8.  Improving the treatment of infant pain.

Authors:  Fiona Moultrie; Rebeccah Slater; Caroline Hartley
Journal:  Curr Opin Support Palliat Care       Date:  2017-06       Impact factor: 2.302

9.  How effective is tetracaine 4% gel, before a venipuncture, in reducing procedural pain in infants: a randomized double-blind placebo controlled trial.

Authors:  Brigitte Lemyre; Debora L Hogan; Isabelle Gaboury; Rebecca Sherlock; Colline Blanchard; David Moher
Journal:  BMC Pediatr       Date:  2007-02-08       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.